The viral envelope glycoprotein gpl20 is responsible for the initial events in HIV-1 infection. In its unliganded state, gpl20 is characterized by the presence of intrinsically disordered domains. In particular, the residues that define the co-receptor binding epitope are disordered and only become binding competent when CD4 binds gp 120. The rational design and optimization of inhibitors require a precise knowledge ofthe contribution of each residue at the gp120/CD4 interface to the binding affinity and to the allosteric structuring process. These issues are addressed in terms of the following specific aims: 1. Thermodynamic characterization of the structural stability and cooperative linkage between binding sites in trimeric (solution and membrane bound) and monomeric gp 120 by utilizing a combination of microcalorimetric and structure-based thermodynamic studies. How do intersubunit interactions within the trimer modulate the functional behavior of gp 120? 2. Thermodynamic characterization of conformational changes associated with receptor, co-receptor and inhibitor binding in trimeric (solution and membrane bound) gp 120. These studies will utilize differential scanning calorimetry, isothermal titration calorimetry and spectroscopic probes. 3. CD4 binding allosterically activates gp 120 by triggering a major conformational change. What are the binding hotspots within the CD4/gp120 binding footprint? Do they overlap with the residues that initiate the allosteric cascade? Themodynamic-based alanine scanning mutagenesis will be used to identify binding and allosteric hotspots. Can we inhibit gp120 binding without triggering the allosteric activation cascade? Are the binding and allosteric hotspots the same in the monomer and trimer? Does the membrane affect the interactions? This fundamental information will drive the computational and synthetic components of the POI. 4. Development of thermodynamic guidelines for the design of highly potent, energy efficient gp 120 inhibitors. The thermodynamic signature of all inhibitor candidates will be determined calorimetrically as it captures the essential properties of inhibitors and can be used for further inhibitor optimization. 5. Development of thermodynamic guidelines for gp120 inhibitors that are effective against different HIV-1 subtypes and exhibit low susceptibility to potential drug resistant mutants.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Program Projects (P01)
Project #
5P01GM056550-18
Application #
8740490
Study Section
Special Emphasis Panel (ZRG1-AARR-E)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
18
Fiscal Year
2014
Total Cost
$305,624
Indirect Cost
$116,967
Name
Drexel University
Department
Type
DUNS #
002604817
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Castillo-Menendez, Luis R; Witt, Kristen; Espy, Nicole et al. (2018) Comparison of Uncleaved and Mature Human Immunodeficiency Virus Membrane Envelope Glycoprotein Trimers. J Virol 92:
Rashad, Adel A; Song, Li-Rui; Holmes, Andrew P et al. (2018) Bifunctional Chimera That Coordinately Targets Human Immunodeficiency Virus 1 Envelope gp120 and the Host-Cell CCR5 Coreceptor at the Virus-Cell Interface. J Med Chem 61:5020-5033
Moraca, Francesca; Rinaldo, David; Smith 3rd, Amos B et al. (2018) Specific Noncovalent Interactions Determine Optimal Structure of a Buried Ligand Moiety: QM/MM and Pure QM Modeling of Complexes of the Small-Molecule CD4 Mimetics and HIV-1 gp120. ChemMedChem 13:627-633
Castillo-Menendez, Luis R; Nguyen, Hanh T; Sodroski, Joseph (2018) Conformational Differences Between Functional Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Trimers and Stabilized Soluble Trimers. J Virol :
Madani, Navid; Princiotto, Amy M; Mach, Linh et al. (2018) A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge. Nat Commun 9:2363
Kisalu, Neville K; Idris, Azza H; Weidle, Connor et al. (2018) A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nat Med 24:408-416
Parajuli, Bibek; Acharya, Kriti; Bach, Harry C et al. (2018) Restricted HIV-1 Env glycan engagement by lectin-reengineered DAVEI protein chimera is sufficient for lytic inactivation of the virus. Biochem J 475:931-957
Ma, Xiaochu; Lu, Maolin; Gorman, Jason et al. (2018) HIV-1 Env trimer opens through an asymmetric intermediate in which individual protomers adopt distinct conformations. Elife 7:
Madani, Navid; Princiotto, Amy M; Zhao, Connie et al. (2017) Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds. J Virol 91:
Prévost, Jérémie; Zoubchenok, Daria; Richard, Jonathan et al. (2017) Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses. J Virol 91:

Showing the most recent 10 out of 146 publications